Patents
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
03/2011
03/29/2011US7914818 Prevent drug abruse; side effect reduction; administering mixture of opioid antagonist, releasable form and sequestering agent
03/29/2011US7914817 Treatment of inflammatory bowel disease
03/29/2011US7914802 Mucosal vaccine adjuvants containing bacterial flagellins as an active component
03/29/2011US7914801 Metabolizable oil emulsion adjuvants and vaccines for enhancing immuno-properties of antibodies and their subpopulations
03/29/2011US7914799 Anti-fungal composition
03/29/2011US7914791 Vaccine
03/29/2011US7914537 Devices and methods for the restoration of a spinal disc
03/29/2011CA2448083C Liquid preparations of fudosteine
03/29/2011CA2443672C Aryl and biaryl piperidines used as mch antagonists
03/29/2011CA2436764C Rehydration composition
03/29/2011CA2434616C (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions and uses thereof
03/29/2011CA2418784C Use of compounds derived from the genus euphorbia for the treatment of carcinoma of the bladder
03/29/2011CA2397016C Use of lipid conjugates in the treatment of disease
03/29/2011CA2390652C Human circulating virus-inhibiting peptide (virip) and its use
03/29/2011CA2379508C Biphasic skin composition comprising ascorbic acid, ceramides and betaglycane
03/29/2011CA2345276C Flt4 (vegfr-3) as a target for tumor imaging and anti-tumor therapy
03/29/2011CA2323058C Methods for the diagnosis and treatment of lung cancer by detection of proto-oncogene overexpression
03/29/2011CA2263798C G-coupled receptor showing selective affinity for atp
03/29/2011CA2239151C Integrin-linked kinase, its inhibitors and methods of medical treatment using these inhibitors, gene therapy and pseudo-substrate inhibitors
03/24/2011WO2011034210A1 Pharmaceutical combination for treating tumor
03/24/2011WO2011033884A1 Prophylactic agent for muscular contracture
03/24/2011WO2011032984A1 Lubiprostone for obstetrical or gynecological applications
03/24/2011WO2011032912A1 Pharmaceutical composition having the active substances metformin and sitagliptin or vildaliptin
03/24/2011WO2009158499A3 Prevention of bacterial growth and biofilm formation by ligands that act on cannabinoidergic systems
03/24/2011WO2009143174A3 Chemical permeation enhancers enhance nerve blockade by toxins
03/24/2011US20110071612 Anti-angiogenic compositions and methods of use
03/24/2011US20110071168 Nitric oxide donors for inducing neurogenesis
03/24/2011US20110071111 Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndrome
03/24/2011US20110071102 Compositions and Methods to Treat Recurrent Medical Conditions
03/24/2011US20110071081 Methods useful in the treatment of bone resorption diseases
03/24/2011US20110071078 Methods for treating neurological deficits
03/24/2011US20110070316 Antimicrobial Compositions Containing Synergistic Combinations of Quaternary Ammonium Compounds and Essential Oils and/or Constituents Thereof
03/24/2011US20110070306 Antimicrobial nanoemulsion compositions and methods
03/24/2011US20110070289 Adaptable modified virus vector to deliver modified messenger ribonucleic acid as a medical treatment device to manage diabetes mellitus and other protein deficient diseases
03/24/2011US20110070162 Rna interference mediating small rna molecules
03/24/2011CA2774149A1 Lubiprostone for obstetrical or gynecological applications
03/24/2011CA2774118A1 Pharmaceutical composition having the active substances metformin and sitagliptin or vildagliptin
03/24/2011CA2772314A1 Pharmaceutical combination for treating tumor
03/23/2011EP2298812A2 Remedies for juvenile chronic arthritis and related diseases
03/23/2011EP2298803A2 Human G-protein coupled receptor and ligands thereof
03/23/2011EP2298790A1 Daptomycin analogs as antibacterial agents
03/23/2011EP2298761A1 HIV inhibiting pyrimidines derivatives
03/23/2011EP2298359A1 Nucleic acid capable of controlling degranulation of mast cell
03/23/2011EP2298350A2 Composition comprising an inducing agent and an anti-viral agent for the treatment of viral disorders
03/23/2011EP2298349A1 Surfactant treatment regimen for treating or preventing bronchopulmonary dysplasia
03/23/2011EP2298346A2 Human antibodies specific to kdr and uses thereof
03/23/2011EP2298334A2 Tweak receptor
03/23/2011EP2298333A2 Tweak receptor
03/23/2011EP2298332A1 BAFF, inhibitors thereof and their use in the modulation of the B-cell response
03/23/2011EP2298306A1 A method of analgesia
03/23/2011EP2298301A2 Medicaments for increasing endogenous Erythropoietin (EPO)
03/23/2011EP2298300A1 Compositions for inhibition of anglogenesis comprising thalidomide and aspirin
03/23/2011EP2298299A2 O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders
03/23/2011EP2298298A2 Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
03/23/2011EP2298297A1 Combination of an inhibitor of the If current of the sinus node and an inhibitor of the angiotensin converting enzyme
03/23/2011EP2298282A1 Combination of drugs having different physical properties into single dosage form
03/23/2011EP2298280A2 Gel comprising a combination of flurbiprofen and muscle relaxant
03/23/2011EP2297183A1 Treatment for diseases relying on discovery that thioredoxin mediates nitric oxide release in cells
03/23/2011EP2296670A1 Glycosaminoglycan oral use and compositions
03/23/2011EP2296661A1 Sgc stimulators, sgc activators and combinations thereof for the treatment of hearing impairment
03/23/2011EP2296645A2 Combination antitumor therapy
03/23/2011EP2296642A1 Compositions comprising amino acids, with pro-angiogenic activity
03/23/2011EP2296640A1 Methods for preventing the development of retinopathy by the oral administration of nnr ligands
03/23/2011EP2296633A2 The use of solid carrier particles to improve the processability of a pharmaceutical agent
03/23/2011EP2296470A2 Compositions and methods for inhibiting gastric acid secretion
03/23/2011EP2023918B1 Cyclosporins for the treatment and prevention of ocular disorders
03/23/2011EP1772145B1 Method of effectively using medicine and method concerning prevention of side effect
03/23/2011EP1552462B1 Methods of treating and preventing colitis involving il-13 and nk-t cells
03/23/2011EP1469878B1 Fgfr agonists
03/23/2011EP1448205B1 Combinations for the treatment of immunoinflammatory disorders
03/23/2011EP1351707B1 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
03/23/2011EP1320386B1 A novel cationic lipopolymer as biocompatible gene delivery agent
03/23/2011EP1320377B1 Hla binding peptides and their uses
03/23/2011CN1981031B Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses
03/23/2011CN101990450A Use of lipid-rich nutrition for the treatment of post-operative ileus
03/23/2011CN101990432A Bitherapy and tritherapy used for treating an hiv-positive patient
03/23/2011CN101987200A Compound medicine containing antihypertensive peptide and aldosterone receptor antagonist for curing hypertension
03/23/2011CN101987199A Antipyretic and analgesic injection composition
03/23/2011CN101987198A Medicinal composition
03/23/2011CN101987197A Method and reagent for inhibiting invasiveness of cancer cells
03/23/2011CN101987111A Composition of cisplatin in combination with 2,2'-dithio-bis(ethanesulfonate) (dimesna)
03/23/2011CN101987085A High-efficiency adhesive powder for treating livestock and poultry diseases
03/23/2011CN101987083A Preparation method for controlled release preparation, especial for zero-order release controlled release preparation
03/23/2011CN101313873B Biology polypeptide medicament blood vessel bracket and preparation method thereof
03/22/2011US7910709 Thyroid stimulating hormone for use in diagnosis, prevention and treatment of thyroid gland disorders
03/22/2011US7910626 Use of S1P receptor agonists in heart diseases
03/22/2011US7910594 Antiproliferative agents; gene overexpression
03/22/2011US7910586 Drug screening; administering secretase inhibitor; Alzheimer's disease
03/22/2011US7910580 Antitumor agents, anticancer agents; synergistic mixture; side effect reduction; inhibiting tumor growth in cancer patient by administering a combination therapy comprising 5-Fluorouracil (5-FU) and a methylol transfer agent capable of enhancing antineoplastic effect of 5-FU
03/22/2011US7910562 Method of delivering genes into antigen presenting cells of the skin
03/22/2011US7910370 Treating and preventing cell proliferative, neurodegenerative and viral infections via enhancing oncogenic protein expression
03/22/2011US7910139 Compositions for the treatment of affections of the oral cavity and upper respiratory tract
03/22/2011US7910097 Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) and uses thereof
03/22/2011CA2490531C Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity
03/22/2011CA2488001C 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the treatment of eye diseases such as glaucoma
03/22/2011CA2484275C Warming and nonirritating lubricant compositions and method of comparing irritation
03/22/2011CA2480273C Ph-sensitive polymer
03/22/2011CA2473885C Use of ambroxol in the treatment of chronic pains, cerebral excitotoxicity-related disorders and cardiac arrhythmias
03/22/2011CA2471543C Non-nucleosidic inhibitors of reverse transcriptase as antagonists of cell proliferation and inducers of cell differentiation
03/22/2011CA2471538C Pyrrolopyrimidines